Drugs / AG-270
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03435250 | Mar 2018 → Apr 2023 | cancer, lymphoma | Servier | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-10-27 | Agios Pharmaceuticals, Inc. | Results Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors agios.com ↗ |
| 2017-12-26 | Agios Pharmaceuticals, Inc. | Regulatory Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation agios.com ↗
Company Also Announces FDA Clearance of Investigational New Drug Application (IND) for AG-270 Targeting MTAP-Deleted Tumors; Phase 1 Study to Initiate in First Quarter 2018 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-10-27 | Agios Pharmaceuticals, Inc. | Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors agios.com ↗ |
| 2019-10-09 | Agios Pharmaceuticals, Inc. | Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference agios.com ↗ |
| 2018-03-19 | Agios Pharmaceuticals, Inc. | Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion agios.com ↗ |
| 2017-12-26 | Agios Pharmaceuticals, Inc. | Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation agios.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG-270 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03435250 ↗ |
| Known as | S095033 | “AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM.” PMID 39762248 ↗ Jan 2025 |
| Action | Inhibit | “AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM.” PMID 39762248 ↗ Jan 2025 |
| Route | Oral | “AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM.” PMID 39762248 ↗ Jan 2025 |
| Target | MAT2A | “AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM.” PMID 39762248 ↗ Jan 2025 |